74 |
New Paradigms in Treatment of ACS/AMI |
Roxana Mehran |
Jul. 22. 09 |
73 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
May. 13. 09 |
72 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
May. 13. 09 |
71 |
Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice? |
David Joel Cohen |
May. 13. 09 |
70 |
What Is the Optimal Duration of Dual Antiplatelet Therapy Following DES Treatment? |
David E. Kandzari |
May. 13. 09 |
69 |
Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel? |
Seung-Whan Lee |
May. 13. 09 |
68 |
Polymorphism in Metabolism of Clopidogrel and Its Clinical Implication and Management |
Alexandra J. Lansky |
May. 13. 09 |
67 |
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? |
Matthew Price |
May. 13. 09 |
66 |
HDL therapy via plasmapheresis |
|
Jan. 07. 09 |
65 |
SEARCH trial |
|
Jan. 07. 09 |